WhichPeps

BAM15

Small-molecule mitochondrial protonophore/uncoupler

Obesityinsulin resistance and…
Generic peptide vial illustrationBAM15
Evidence levelPreclinical only
Human evidenceNone established
Regulatory statusNo FDA/EMA approval identified

What you need to know in 20 seconds

What is it?Small-molecule mitochondrial protonophore/uncoupler
Research focusObesity, insulin resistance and metabolic research
Human evidenceNo therapeutic human trial evidence was identified.
Regulatory statusNo FDA/EMA-approved medicine identified.
Main limitationsHuman efficacy, dose, therapeutic window, chronic safety or suitability as an oral lifestyle compound.
SafetyMitochondrial uncoupling is intrinsically safety-sensitive; human therapeutic window, cardiac/thermal risks and chronic toxicity are unknown.
i
No therapeutic human trial evidence was identified.

What the evidence actually supports

  • Treat as high-interest preclinical science, not a lifestyle treatment.

What is not established / key limitations

  • ×No human clinical trial evidence identified.

Selected study & evidence records

Discovery of BAM15 mitochondrial uncoupler

2014 · Preclinical mechanistic/animal study

BAM15 uncoupled mitochondrial respiration without the same plasma-membrane depolarization seen with some comparator uncouplers and showed mouse bioactivity.

Study detail → Primary source ↗

BAM15-mediated uncoupling in diet-induced obesity

2020 · Preclinical animal efficacy study

BAM15 protected mice against diet-induced weight gain and improved metabolic measures.

Study detail → Primary source ↗

Safety and unknowns

Mitochondrial uncoupling is intrinsically safety-sensitive; human therapeutic window, cardiac/thermal risks and chronic toxicity are unknown.

Mitochondrial uncoupling is intrinsically safety-sensitive; human therapeutic window, thermal/cardiac risk and chronic toxicity are unknown despite preclinical selectivity claims.

Technical details

Mechanism / biologyMitochondrial protonophore that increases energy expenditure by partially uncoupling oxidative phosphorylation in experimental models.
Route / formulation boundaryThis is not a peptide; commercial oral products have no established clinical validation.
Identity / data-quality noteUse the canonical compound identity and studied formulation when interpreting evidence.
Dosing evidence statusDosing research conclusion recorded. No human systemic administration regimen identified; human-derived-cell and preclinical work do not establish a human dose or safety window.

Evidence rule: WhichPeps keeps human, animal, laboratory, regulatory and product/formulation evidence distinct. Common names help people find the page; they do not change the underlying scientific identity.